Point mutation (-69 G→ A) in the promoter region of cholesteryl ester transfer protein gene in Japanese hyperalphalipoproteinemic subjects

被引:25
|
作者
Nagano, M
Yamashita, S
Hirano, K
Kujiraoka, T
Ito, M
Sagehashi, Y
Hattori, H
Nakajima, N
Maruyama, T
Sakai, N
Egashira, T
Matsuzawa, Y
机构
[1] Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Suita, Osaka 5650871, Japan
[2] Nakajima Clin, Akita, Japan
关键词
cholesteryl ester transfer protein deficiency hyperalphalipoproteinemia; mutation; promoter; PEA3/ETS binding site;
D O I
10.1161/01.ATV.21.6.985
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cholesteryl ester transfer protein (CETP) transfers cholesteryl ester (CE) from HDL to apolipoprotein (apo) B-containing lipoproteins and plays a crucial role in reverse cholesterol transport, which is a major protective system against atherosclerosis. Genetic CETP deficiency is the most common cause of a marked hyperalphalipoproteine mia (HALP) in the Japanese, and various mutations have been identified in the coding region as well as in the exon/intron boundaries in the CETP gene. In the present study, we identified a novel mutation in the promoter region of the CETP gene. This mutation was a G-to-A substitution at the -69 nucleotide of the promoter region (-69 G -->A). corresponding to the second nucleotide of the PEA3/ETS binding site (CGGAA) located upstream of the putative TATA box. Four (2.0%) of 196 unrelated subjects with a marked HALF (HDL cholesterol greater than or equal to2.59 mmol/L=100 mg/dL) were revealed to be heterozygous for the -69 G -->A mutation, and the allelic frequency of the mutant was 0.0102 in the subjects with a marked HALF. The subjects with the -69 G -->A mutation had low plasma CETP levels. Reporter gene assay showed that this mutation markedly reduced the transcriptional activities in HepG2 cells (8% of wild type). These results suggested that this mutation would be dominant negative. In conclusion, a novel -69 G -->A mutation in the CETP gene causes the decreased transcriptional activity leading to HALP.
引用
收藏
页码:985 / 990
页数:6
相关论文
共 50 条
  • [11] A cholesteryl ester transfer protein gene mutation and vascular disease in dialysis patients
    Kimura, H
    Gejyo, F
    Yamaguchi, T
    Suzuki, S
    Imura, T
    Miyazaki, K
    Arakawa, M
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1999, 10 (02): : 294 - 299
  • [12] The role of a variant of the cholesteryl ester transfer protein gene in the progression of macrovascular complications in Japanese type 2 diabetic subjects
    Kawasaki, I
    Tahara, H
    Emoto, M
    Shoji, T
    Komatsu, M
    Nishizawa, Y
    DIABETES, 2001, 50 : A157 - A157
  • [13] Polymorphism of the cholesteryl ester transfer protein gene
    Goldstein, MR
    NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (22): : 1624 - 1625
  • [14] Association of cholesteryl ester transfer protein activity and TaqIB polymorphism with lipoprotein variations in Japanese subjects
    Ikewaki, K
    Mabuchi, H
    Teramoto, T
    Yamada, N
    Oikawa, S
    Sasaki, J
    Takata, K
    Saito, Y
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2003, 52 (12): : 1564 - 1570
  • [15] Characterization of two distinct hyperalphalipoproteinemic (HALP) profiles without cholesteryl ester transfer protein (CETP) deficiency
    Sich, D
    Saidi, Y
    Beucler, I
    Giral, P
    Cherfils, C
    Egloff, M
    Turpin, G
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 373 - 374
  • [16] Pharmacogenetic Study of Cholesteryl Ester Transfer Protein Gene and Atorvastatin Treatment in Hypercholesterolemic Subjects
    Kolovou, Genovefa
    Vasiliadis, Ioannis
    Anagnostopoulou, Katherine
    Kostakou, Peggy
    Mihas, Costantinos
    Stamatelatou, Mariana
    Diakoumakou, Olga
    Kolovou, Vana
    Mavrogeni, Sophie
    Mikhailidis, Dimitris
    CIRCULATION, 2010, 122 (02) : E270 - E270
  • [17] Pharmacogenetic study of cholesteryl ester transfer protein gene and simvastatin treatment in hypercholesterolaemic subjects
    Anagnostopoulou, Katherine
    Kolovou, Genovefa
    Kostakou, Peggy
    Mihas, Constantinos
    Mikhailidis, Dimitri
    Cokkinos, Dennis V.
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (15) : 2459 - 2463
  • [18] Variability in cholesteryl ester transfer protein in healthy Japanese hyper-HDL-cholesterolemic subjects
    Yoshida, A
    Kodama, M
    Nomura, H
    Kobayashi, N
    Sumida, K
    Naito, M
    INTERNAL MEDICINE, 2002, 41 (05) : 357 - 359
  • [19] PHARMACOGENETIC STUDY OF CHOLESTERYL ESTER TRANSFER PROTEIN GENE AND ATORVASTATIN TREATMENT IN HYPERCHOLESTEROLAEMIC SUBJECTS
    Anagnostopoulou, K.
    Kolovou, G.
    Kostakou, P.
    Kolovou, V.
    Stamatelatou, M.
    Mihas, C.
    Vasiliadis, I.
    Diakoumakou, O.
    Mikhailidis, D.
    Cokkinos, D.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [20] Prevalence and phenotypic spectrum of cholesteryl ester transfer protein gene mutations in Japanese hyperalphalipoproteinemia
    Maruyama, T
    Sakai, N
    Ishigami, M
    Hirano, K
    Arai, T
    Okada, S
    Okuda, E
    Ohya, A
    Nakajima, N
    Kadowaki, K
    Fushimi, E
    Yamashita, S
    Matsuzawa, Y
    ATHEROSCLEROSIS, 2003, 166 (01) : 177 - 185